Compare Petróleo Brasileiro SA (PBR) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Petróleo Brasileiro SA vs TransMedics Group Inc — how do they compare? Petróleo Brasileiro SA trades at $25.26 (market cap $151.94B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: Petróleo Brasileiro SA is far larger — about 55.5× TransMedics Group Inc's market cap, and Petróleo Brasileiro SA pays a 6.79% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Petróleo Brasileiro SA for 25 Days and TransMedics Group Inc for 24 Days on average.
| PBR | TMDX | |
|---|---|---|
Market Cap | $151.94B | $2.74B |
Volume | 30,240,092 | 949,331 |
Sector | Energy | Health |
52-Week High | $24.69 | $150.42 |
52-Week Low | $11.54 | $61.99 |
Typical Hold Time | 25 Days | 24 Days |
Enterprise Value | $212.36B | $3.13B |
Dividend Yield | 6.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Petrobras (PBR) trades at $25.30, up 5.46% in the past 24 hours, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with a P/E of 6.24, net income margin of 24.52%, and ROE of 30.77%. Recent developments include new oil discoveries and platform deployments that support production growth.
The outlook remains positive with revenue projected to grow from $89.2B in 2025 to $104.2B in 2026. Risks include capital expenditure pressures and political exposure in Brazil. Analyst consensus is bullish with 50% buy ratings and a $22.33 price target, though the current price exceeds this target.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
